Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128640 | 0.93 | CYP1A2 (0.56) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 | |
| SCHEMBL1487677 | 0.88 | SIGMAR1 (0.53) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 | |
| SCHEMBL1611323 | 0.86 | SIGMAR1 (0.51) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 | |
| SCHEMBL1611043 | 0.84 | SIGMAR1 (0.50) | CYP1A2CYP2A6SIGMAR1HRH3HDAC1 | |
| SCHEMBL1612447 | 0.84 | SIGMAR1 (0.50) | CYP1A2CYP2A6SIGMAR1HRH3HDAC1 | |
| SCHEMBL1610204 | 0.84 | SIGMAR1 (0.50) | CYP1A2CYP2A6SIGMAR1HRH3HDAC1 | |
| SCHEMBL1611744 | 0.82 | CYP1A2 (0.52) | CYP1A2CYP2A6SIGMAR1HRH3ALDH1A1 | |
| SCHEMBL128560 | 0.81 | SIGMAR1 (0.59) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 | |
| SCHEMBL133399 | 0.79 | SIGMAR1 (0.58) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 | |
| SCHEMBL6240981 | 0.79 | CYP1A2 (0.65) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718758-B2 | Aqueous dispersion of colored particles | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2023-08-08 | — | — | US | disclosed |
| EP-3725854-B1 | COLORED PARTICLE AQUEOUS DISPERSION | MITSUBISHI PENCIL CO (JP) | 2023-07-05 | — | — | EP | disclosed |
| CN-111465662-B | Aqueous dispersion of coloured particles | 三菱铅笔株式会社 | 2023-05-26 | — | — | CN | disclosed |
| EP-3020715-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-20210071006-A1 | AQUEOUS DISPERSION OF COLORED PARTICLES | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-10913855-B2 | Silicon-containing heterocyclic compound, and quencher | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2021-02-09 | — | — | US | disclosed |
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| EP-3725854-A1 | COLORED PARTICLE AQUEOUS DISPERSION | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-10377713-B2 | Quencher | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-08-13 | — | — | US | disclosed |
| US-20190233651-A1 | SILICON-CONTAINING HETEROCYCLIC COMPOUND, AND QUENCHER | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20030153783-A1 | Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2003-08-14 | — | — | US | disclosed |
| US-6589939-B2 | Also useful in treating viral infections; antiprotozoa (plasmodium) activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-07-08 | — | — | US | disclosed |
| US-6528684-B1 | Blocking amino group, cyclizing to anhydride, decarbonylation lactonation, hydrolysis, dehydroxylation quaternation using trimethyl ammonium halide, converting to internal carboxylic amine salt and deblocking | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-03-04 | — | — | US | disclosed |
| EP-1044977-B1 | Camptothecin derivatives having antitumor activity | SIGMA TAU IND FARMACEUTI (IT) | 2002-05-02 | — | — | EP | disclosed |
| EP-1194398-A1 | SYNTHESIS OF (R) AND (S)-AMINOCARNITINE AND THEIR DERIVATIVES STARTING FROM D- AND L-ASPARTIC ACID | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-04-10 | — | — | EP | disclosed |
| US-20010008939-A1 | Camptothecin derivatives having antitumor activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.. | 2001-07-19 | — | — | US | disclosed |
| US-6242457-B1 | OXIME DERIVATIVES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-06-05 | — | — | US | disclosed |
| WO-2001002341-A1 | SYNTHESIS OF (R) AND (S)-AMINOCARNITINE AND THEIR DERIVATIVES STARTING FROM D- AND L-ASPARTIC ACID | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-01-11 | — | — | WO | disclosed |
| EP-1044977-A1 | Camptothecin derivatives having antitumor activity | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2000-10-18 | — | — | EP | disclosed |
| WO-2000053607-A1 | CAMPTOTHECIN DERIVATIVES HAVING ANTITUMOR ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377713-B2 | Quencher | AHR, GFER, AKR1A1 | CYP1A2 56/4885CYP2A6 136/4885SIGMAR1 410/4885 |
| US-20030153783-A1 | Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid | BCAT1, BCAT2, DDC | CYP1A2 4691/4885CYP2A6 3134/4885SIGMAR1 2801/4885 |
| US-10913855-B2 | Silicon-containing heterocyclic compound, and quencher | ANXA11, ANXA1, ORAI2 | CYP1A2 652/4885CYP2A6 1875/4885SIGMAR1 129/4885 |
| US-20010008939-A1 | Camptothecin derivatives having antitumor activity | TOP1, TOP2A, TYMP | CYP1A2 3186/4885CYP2A6 4187/4885SIGMAR1 3070/4885 |
| US-20190233651-A1 | SILICON-CONTAINING HETEROCYCLIC COMPOUND, AND QUENCHER | ANXA11, ANXA1, ORAI2 | CYP1A2 678/4885CYP2A6 1922/4885SIGMAR1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.